From stockwatch:
Capital Pro-Egaux licenses patents to nSequence et al.
2017-01-10 11:21 ET - News Release
Mr. Pierre Desormeau reports
CAPITAL PRO-EGAUX INC. (NEX: CPE.H) ANNOUNCES THE CONCLUSION OF A LICENSE AGREEMENT WITH NSEQUENCE CENTER FOR ADVANCED DENTISTRY AND NATIONAL DENTEX CORPORATION
Capital Pro-Egaux Inc.'s wholly owned subsidiary, Technique d'usinage Sinlab Inc., has entered into a patent licence agreement with nSequence Center for Advanced Dentistry and National Dentex Corp. As part of the agreement, Sinlab granted licensees a non-exclusive worldwide licence to make, use, sell and offer to sell inventions covered by its patents, including patents relating to its Technobar and Technoguide technologies, under terms undisclosed for confidentiality reasons.
Unlicensed entities should obtain an appropriate license from Sinlab by contacting M. Jean Kingsley at jeanjkingsley@outlook.com.
The Company previously announced settlement and/or license agreements that include Biomet 3i, LLC (formerly Implant Innovations, Inc.); Delcam USA, Inc. and Delcam Holdings, Inc.; Cagenix, Inc.; Dentsply International Inc.; Nobel Biocare AB; Nobel Biocare Italiana S.r.l.; Nobel Biocare Holding AG; Nobel Biocare Deutschland GmbH; Nobel Biocare Canada, Inc.; Biocad Medical Inc.; Nobel Biocare USA, LLC; Nobel Biocare Procera, LLC; 3Shape A/S, exocad America, Inc., MIS Implants Technologies, Ltd., SICAT Gmbh & Co. KG and James R. Glidewell Dental Ceramics, Inc. The Company is currently pursuing its licensing program with other industry participants. The Company cannot predict the outcome of its ongoing negotiations or of any legal proceedings it may decide to institute against those entities that fail or refuse to contract a license. The decision to take legal proceedings will be based on available information and the Company's assessment of all relevant facts and circumstances, including costs involved with such proceedings. Such costs are unpredictable and may be substantial.
We seek Safe Harbor.